AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 MAY 16 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - Immune response of prostate cancer patients receiving a dendritic cell (DC) vaccine varies depending on how the vaccine is delivered, pathologists report.
Intradermal and intralymphatic routes of administration were more likely to induce interferon-gamma production, while intravenous injection was better at generating antigen (Ag)-specific antibodies (Abs), noted L. Fong and colleagues at Stanford University.
They used Ag-pulsed DC as a tumor vaccine in a pilot clinical trial involving 21 patients with metastatic prostate cancer. The patients received two monthly injections of DC derived from their peripheral blood mononuclear cells and cultured ex vivo with mouse prostatic acid phosphatase.
Three groups of patients were immunized with this vaccine either intravenously, intradermally, or intralymphatically. Although they all developed Ag-specific T-cell immune responses, only intralymphatic and intradermal routes led to interferon-gamma production.
Five of nine patients who were immunized intravenously, on the other hand, developed Ag-specific antibodies, compared with one of six for intradermal and two of six for intralymphatic routes ("Dendritic cells injected via different routes induce immunity in cancer patients," J ...